Quantitative Biosciences Institute Appoints Brad Schneider, Ph.D., as Chief Operating Officer

—Infectious disease scientist, R&D executive, and global health strategist joins QBI to lead operational excellence and institutional growth—

SAN FRANCISCO--(BUSINESS WIRE)--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced the appointment of Brad Schneider, Ph.D., as Chief Operating Officer. Dr. Schneider brings more than two decades of experience in infectious disease research, global health operations, and scientific program leadership to his new role.

"Brad brings something rare to QBI, a scientist's instincts and an operator's discipline," said Nevan J. Krogan, Ph.D., Director, QBI. "He has spent his career building and leading diverse, high-performing teams across some of the world's most demanding scientific environments, always with an eye on the science and its translational impact on human health globally. We are delighted to welcome him to QBI as we enter this next important phase of our growth and impact."

Dr. Schneider joins QBI from Vaccines for Communities (V4C), a global biotechnology company developing a new generation of pediatric mRNA vaccines targeting dengue fever, where he served as Chief Executive Officer, leading the company's strategic and operational framework, global partnerships and fundraising. Prior to that, he served as Chief Executive Officer at Pinpoint Science, where he directed all scientific, operational, and regulatory activities and spearheaded the development and validation of a novel bioelectronic diagnostic device.

Earlier in his career, he held senior science and leadership roles including Chief Scientific Officer at Renegade Bio and Science Integration Lead at Metabiota. At Metabiota, he managed scientific activities across eight international field teams spanning Southeast Asia and Africa, oversaw more than 150,000 diagnostic tests for 25+ pathogens, and provided strategic direction for USAID’s PREDICT program, a $100 million global effort for emerging pathogen detection and early warning. He also contributed to the development of a global health threat detection and modeling platform integrating natural language processing, epidemiological modeling, and risk analytics, acquired by Ginkgo Bioworks. Dr. Schneider maintains an active independent consulting practice in global health security and emerging infectious diseases, working with the U.S. Department of Defense, PATH, and GAVI, on strategic planning, health systems strengthening, and biosafety and biosecurity.

Dr. Schneider began his scientific career as an Emerging Infectious Disease Fellow at the CDC's Division of Vector-Borne Infectious Disease and conducted doctoral research at the University of Texas Medical Branch's Regional Center of Excellence for Biodefense and Emerging Infectious Diseases. He served as a Visiting Scientist and Pasteur Foundation Fellow at the Institut Pasteur in Paris, where he worked in the Virus Pathogenesis Unit. Dr. Schneider holds a Ph.D. in Experimental Pathology and Virology from the University of Texas Medical Branch and a B.A. in Molecular, Cellular and Developmental Biology and Psychology from the University of Colorado, Boulder.

“QBI has built something genuinely extraordinary, a platform that connects cutting-edge quantitative and systems biology to some of the most urgent challenges in human health, from cancer to neurodegeneration to pandemic preparedness,” stated Dr. Schneider. “What excites me most is that the institute is at a real inflection point: the convergence of proteomics, AI, and global scientific collaboration is creating opportunities for impact that weren't possible even a few years ago. I'm thrilled to help build the operational infrastructure that allows QBI to fully realize that potential.”

ABOUT THE QUANTITATIVE BIOSCIENCES INSTITUTE (QBI)

The Quantitative Biosciences Institute (QBI) is a University of California organized research unit reporting through the UCSF School of Pharmacy. QBI fosters collaborations across the biomedical and physical sciences to advance interdisciplinary approaches to human disease and therapeutic discovery. QBI’s disease-agnostic, uniquely integrated technological platforms have generated insights across cancer, neurodegeneration, and infectious diseases, leading to the formation of spinout companies, including Rezo Therapeutics. QBI incorporates the UCSF division of QB3, a multicampus UC institute that supports bioscience research and innovation in California. Learn more at qbi.ucsf.edu.